Literature DB >> 23730877

Lipoxin A4: a new direction in asthma therapy?

Cindy Barnig, Bruce D Levy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730877     DOI: 10.1586/eci.13.36

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


× No keyword cloud information.
  5 in total

Review 1.  Natural killer cells in inflammatory heart disease.

Authors:  SuFey Ong; Noel R Rose; Daniela Čiháková
Journal:  Clin Immunol       Date:  2016-11-25       Impact factor: 3.969

2.  Lipoxin A4 inhibits NF-κB activation and cell cycle progression in RAW264.7 cells.

Authors:  Yong-Hong Huang; Hong-Mei Wang; Zhen-Yu Cai; Fang-Yun Xu; Xiao-Yan Zhou
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

3.  Pilot application of lipoxin A4 analog and lipoxin A4 receptor agonist in asthmatic children with acute episodes.

Authors:  Xia Kong; Sheng-Hua Wu; Li Zhang; Xiao-Qing Chen
Journal:  Exp Ther Med       Date:  2017-07-12       Impact factor: 2.447

4.  Synthesis of an Electrophilic Keto-Tetraene 15-oxo-Lipoxin A4 Methyl Ester via a MIDA Boronate.

Authors:  Steven R Woodcock; Stacy G Wendell; Francisco J Schopfer; Bruce A Freeman
Journal:  Tetrahedron Lett       Date:  2018-08-10       Impact factor: 2.415

Review 5.  Arachidonic acid: Physiological roles and potential health benefits - A review.

Authors:  Hatem Tallima; Rashika El Ridi
Journal:  J Adv Res       Date:  2017-11-24       Impact factor: 10.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.